No-Fault Compensation for Vaccine Injury — The Other Side of Equitable Access to Covid-19 Vaccines

Halabi, Sam; Heinrich, Andrew; Omer, Saad B.

doi:10.1056/nejmp2030600

Cited by 35 publications

(34 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…65,[85][86][87] Having robust pharmacovigilance systems alongside compensation schemes for severe adverse events might help build confidence in vaccine safety in post-approval periods, especially in resource-poor countries with imperfect consumer protection systems. 88,89 Moreover, disadvantaged groups, many of which have suffered historical neglect and abuse, 90 often report lower levels of trust in the medical community 91,92 and lower uptake of health-care interventions, including vaccines, than the general population. [93][94][95][96] Additional efforts are needed to build trust among these groups.…”

Section: Vaccine Hesitancymentioning

confidence: 99%

Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment

et al. 2021

View full text Add to dashboard Cite

The COVID-19 pandemic is unlikely to end until there is global roll-out of vaccines that protect against severe disease and preferably drive herd immunity. Regulators in numerous countries have authorised or approved COVID-19 vaccines for human use, with more expected to be licensed in 2021. Yet having licensed vaccines is not enough to achieve global control of COVID-19: they also need to be produced at scale, priced affordably, allocated globally so that they are available where needed, and widely deployed in local communities. In this Health Policy paper, we review potential challenges to success in each of these dimensions and discuss policy implications. To guide our review, we developed a dashboard to highlight key characteristics of 26 leading vaccine candidates, including efficacy levels, dosing regimens, storage requirements, prices, production capacities in 2021, and stocks reserved for low-income and middle-income countries. We use a traffic-light system to signal the potential contributions of each candidate to achieving global vaccine immunity, highlighting important trade-offs that policy makers need to consider when developing and implementing vaccination programmes. Although specific datapoints are subject to change as the pandemic response progresses, the dashboard will continue to provide a useful lens through which to analyse the key issues affecting the use of COVID-19 vaccines. We also present original data from a 32-country survey (n=26 758) on potential acceptance of COVID-19 vaccines, conducted from October to December, 2020. Vaccine acceptance was highest in Vietnam (98%), India (91%), China (91%), Denmark (87%), and South Korea (87%), and lowest in Serbia (38%), Croatia (41%), France (44%), Lebanon (44%), and Paraguay (51%).

show abstract

Section: Vaccine Hesitancymentioning

confidence: 99%

Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Expanded worldwide ‘pan-vaccination’ is considered crucial to acquire herd immunity, enabling special measures to be relaxed and safe resumption of dental activity, whilst limiting the risk of serious respiratory complications. As of 10th March 2021, there were more than 200 vaccines in pre-clinical and clinical development [ 50 ], including 21 in phase three trials, six in the early/limited use phase, and six approved for full use [ 51 ]. Equal distribution of the COVID-19 vaccine worldwide seems currently to be a major, unresolved, and time-consuming challenge [ 52 , 53 ].…”

Section: Long-term Prediction: Being Prepared For Health and Dental Care Disruptionmentioning

confidence: 99%

Proposal for Tier-Based Resumption of Dental Practice Determined by COVID-19 Rate, Testing and COVID-19 Vaccination: A Narrative Perspective

Farshidfar

Jafarpour

Hamedani

et al. 2021

JCM

View full text Add to dashboard Cite

Since the emergence of the new coronavirus disease (COVID-19), profound alterations in general and specialist dental practice have been imposed to provide safe dental care. The guidelines introduced in response to the COVID-19 pandemic to mitigate healthcare disruption are inconsistent regarding the dental practice re-installation, particularly during a transitional time. Despite the successful mass vaccination campaigns rolled out in 2021, the presence of more than 80 genotypes of COVID-19, rapid neutralisation of antibodies within a short period of seropositivity, and the likelihood of recurrent infection raise some doubts on whether vaccination alone will provide long-term immunity against COVID-19 and its variants. Here, from this perspective, we aim to provide an initial proposal for dental services reinstallation, easily applicable in various care settings. We discuss the potential options for the transition of dental services, as well as challenges and opportunities to adapt to new circumstances after mass COVID-19 vaccination. The proposal of the universal three-tier system of dental services resumption, determined by regional COVID-19 rates, testing accessibility, and vaccination rollout has been presented. Following herd COVID-19 immunity enhancement, it would be prudent to confer various preventative measures until virus spread naturally diminishes or becomes less virulent. Based on modelling data, dental practices may not return to normal, routine operation even after global vaccination as there would still be a significant risk of outbreaks of infection. Variable, multi-level measures will still be required, depending on the local COVID-19 cases rate, to secure safe dental care provision, despite predicted success of vaccination agendas. This approach can be implemented by achievable, practical means as a part of risk assessment, altered work pattern, and re-arrange of dental surgery facilities. The adequate standard operating procedure, with the support of rapid point-of-care testing at workplace, would vastly intensify the uninterrupted recovery of the dental care sector.

show abstract

“…Adverse events monitoring is the final component of a vaccine program, as rare side effects may only become apparent post-licensure. Public confidence could be further enhanced with a no-fault vaccine compensation scheme, which is a part of many vaccination programs around the world 33 .…”

Section: Ring Vaccinationmentioning

confidence: 99%

Vaccination for COVID-19 control and considerations for Australia

MacIntyre¹

2021

Microbiol. Aust.

View full text Add to dashboard Cite

Vaccines remain the main prospect for an exit strategy from the COVID-19 pandemic, and may, depending on efficacy, duration of protection and uptake, make herd immunity feasible. If herd immunity is not achievable, SARS-COV-2 will circulate long-term. There are many vaccine candidates in development and choices between vaccines that will vary in efficacy and safety. The efficacy of available vaccines is compared and ranges from 62-95% against symptomatic infection with the G614 variant. Efficacy is reduced against new variants of concern and is uncertain against asymptomatic infection. Some vaccines show a better protective immune response than natural infection. The principles of herd immunity and prerequisites for achieving it, such as vaccine efficacy, duration of protection and coverage, are discussed. The alternative vaccine strategies including mass vaccination, targeted risk or age-based vaccination and ring vaccination, as well as speed of vaccination are reviewed. Finally, the impact of variants of concern on vaccine programs and the logistics of mass vaccination are discussed.

show abstract

No-Fault Compensation for Vaccine Injury — The Other Side of Equitable Access to Covid-19 Vaccines

Cited by 35 publications

References 2 publications

Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment

Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment

Proposal for Tier-Based Resumption of Dental Practice Determined by COVID-19 Rate, Testing and COVID-19 Vaccination: A Narrative Perspective

Vaccination for COVID-19 control and considerations for Australia

Contact Info

Product

Resources

About